AVN-101 is under clinical development by Avineuro Pharmaceuticals and currently in Phase II for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase II drugs for Dementia Associated With Alzheimer’s Disease have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVN-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVN-101 overview
AVN-101 is under development for the treatment of generalized anxiety disorder, dementia associated with Alzheimer's disease and cognitive dysfunction. It is administered by the oral route. It is a small molecule and is a multi-module drug candidate that targets 5HT6, 5-HT7, 5-HT2A, 5-HT2C, adrenergic alpha 2A, alpha 2B and alpha 2C receptors. It was also under development for the treatment of Alzheimer’s disease.
See Also:
Avineuro Pharmaceuticals overview
Avineuro Pharmaceuticals (Avineuro), a subsidiary of ChemRar High-Tech Center, discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. It develops novel molecules with pharmacokinetic properties in comparison to late-stage development compounds. It emphasizes an approach that combines modern medical chemistry and pre-clinical and clinical development studies. Avineuro’s pipeline products include AVN-211 for schizophrenia, AVN-322 for cognitive dysfunction, AVN-101 for anxiety disorders and others. The company develops research platforms through strategic partnerships with medical research institutions and contract research organizations. Avineuro is headquartered in San Diego, California, the US.
For a complete picture of AVN-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
